Equities research analysts expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to post $0.15 earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Meridian Bioscience’s earnings, with the highest EPS estimate coming in at $0.15 and the lowest estimate coming in at $0.14. Meridian Bioscience posted earnings of $0.21 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 28.6%. The business is scheduled to report its next earnings report before the market opens on Tuesday, April 30th.
On average, analysts expect that Meridian Bioscience will report full-year earnings of $0.63 per share for the current fiscal year, with EPS estimates ranging from $0.61 to $0.65. For the next year, analysts expect that the company will post earnings of $0.70 per share, with EPS estimates ranging from $0.66 to $0.73. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Meridian Bioscience.
Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, January 24th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. Meridian Bioscience had a net margin of 12.06% and a return on equity of 19.17%. The business had revenue of $51.48 million for the quarter, compared to analyst estimates of $51.50 million. During the same period last year, the business posted $0.15 earnings per share. The firm’s quarterly revenue was down 1.5% on a year-over-year basis.
A number of hedge funds have recently modified their holdings of VIVO. Norges Bank acquired a new stake in Meridian Bioscience in the 4th quarter valued at $22,052,000. Vaughan Nelson Investment Management L.P. acquired a new stake in Meridian Bioscience in the 4th quarter valued at $13,297,000. BlackRock Inc. increased its stake in Meridian Bioscience by 5.6% in the 3rd quarter. BlackRock Inc. now owns 6,228,616 shares of the company’s stock valued at $92,806,000 after buying an additional 327,584 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in Meridian Bioscience in the 4th quarter valued at $3,724,000. Finally, Morgan Stanley increased its stake in Meridian Bioscience by 57.7% in the 3rd quarter. Morgan Stanley now owns 523,950 shares of the company’s stock valued at $7,807,000 after buying an additional 191,623 shares during the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.
Shares of NASDAQ:VIVO opened at $12.86 on Friday. Meridian Bioscience has a 12 month low of $12.70 and a 12 month high of $19.84. The company has a current ratio of 6.75, a quick ratio of 4.72 and a debt-to-equity ratio of 0.24. The firm has a market cap of $554.06 million, a P/E ratio of 17.38 and a beta of 0.49.
About Meridian Bioscience
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Read More: Trading Options- What is a Strangle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.